Zibo Xiong1, Hong Xu2, Xiaoyan Huang3, Johan Ärnlöv4, Abdul Rashid Qureshi2, Tommy Cederholm5, Per Sjögren5, Bengt Lindholm2, Ulf Risérus5, Juan Jesús Carrero6. 1. Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention, and Technology, and Division of Nephrology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China; 2. Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention, and Technology, and. 3. Division of Nephrology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China; 4. Molecular Epidemiology, Department of Medical Sciences, and School of Health and Social Studies, Dalarna University, Falun, Sweden. 5. Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; and. 6. Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention, and Technology, and Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden; juan.jesus.carrero@ki.se.
Abstract
BACKGROUND AND OBJECTIVES: Although nonesterified fatty acids (NEFAs) are essential as energy substrate for the myocardium, an excess of circulating NEFAs can be harmful. This study aimed to assess plausible relationships between serum NEFA and mortality due to cardiovascular disease (CVD) in individuals with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective cohort study from the third examination cycle of the Uppsala Longitudinal Study of Adult Men, a population-based survey of 1221 elderly men aged 70-71 years residing in Uppsala, Sweden. Data collection took place during 1991-1995. All participants had measures of kidney function; this study investigated 623 (51.7%) of these patients with manifest CKD (defined as either eGFR<60 ml/min per 1.73 m(2) or urine albumin excretion rate ≥20 µg/min). Follow-up for mortality was done from examination date until death or December 31, 2007. After a median follow-up of 14 years (interquartile range, 8-16.8), associations of NEFAs with mortality (related to all causes, CVD, ischemic heart disease [IHD], or acute myocardial infarction) were ascertained. RESULTS: The median serum NEFA was 14.1 mg/dl (interquartile range, 11.3-17.8). No association was found with measures of kidney function. Diabetes and serum triglycerides were the only multivariate correlates of NEFA. During follow-up, 453 participants died, of which 209 deaths were due to CVD, including 88 IHD deaths, with 41 attributed to acute myocardial infarction (AMI). In fully adjusted covariates, serum NEFA was an independent risk factor for all-cause mortality (hazard ratio [HR] per log2 increase, 1.22; 95% confidence interval [95% CI], 1.00 to 1.48) and CVD-related death (HR, 1.51; 95% CI, 1.15 to 1.99), including both IHD (HR, 1.51; 95% CI, 1.00 to 2.32) and AMI mortality (HR, 2.08; 95% CI, 1.09 to 3.98). CONCLUSIONS: Elevated serum NEFA associated with CVD mortality, and particularly with mortality due to AMI, in a homogeneous population of older men with moderate CKD.
BACKGROUND AND OBJECTIVES: Although nonesterified fatty acids (NEFAs) are essential as energy substrate for the myocardium, an excess of circulating NEFAs can be harmful. This study aimed to assess plausible relationships between serum NEFA and mortality due to cardiovascular disease (CVD) in individuals with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a prospective cohort study from the third examination cycle of the Uppsala Longitudinal Study of Adult Men, a population-based survey of 1221 elderly men aged 70-71 years residing in Uppsala, Sweden. Data collection took place during 1991-1995. All participants had measures of kidney function; this study investigated 623 (51.7%) of these patients with manifest CKD (defined as either eGFR<60 ml/min per 1.73 m(2) or urine albumin excretion rate ≥20 µg/min). Follow-up for mortality was done from examination date until death or December 31, 2007. After a median follow-up of 14 years (interquartile range, 8-16.8), associations of NEFAs with mortality (related to all causes, CVD, ischemic heart disease [IHD], or acute myocardial infarction) were ascertained. RESULTS: The median serum NEFA was 14.1 mg/dl (interquartile range, 11.3-17.8). No association was found with measures of kidney function. Diabetes and serum triglycerides were the only multivariate correlates of NEFA. During follow-up, 453 participants died, of which 209 deaths were due to CVD, including 88 IHD deaths, with 41 attributed to acute myocardial infarction (AMI). In fully adjusted covariates, serum NEFA was an independent risk factor for all-cause mortality (hazard ratio [HR] per log2 increase, 1.22; 95% confidence interval [95% CI], 1.00 to 1.48) and CVD-related death (HR, 1.51; 95% CI, 1.15 to 1.99), including both IHD (HR, 1.51; 95% CI, 1.00 to 2.32) and AMI mortality (HR, 2.08; 95% CI, 1.09 to 3.98). CONCLUSIONS: Elevated serum NEFA associated with CVD mortality, and particularly with mortality due to AMI, in a homogeneous population of older men with moderate CKD.
Authors: Matteo Pirro; Pascale Mauriège; André Tchernof; Bernard Cantin; Gilles R Dagenais; Jean Pierre Després; Benoît Lamarche Journal: Atherosclerosis Date: 2002-02 Impact factor: 5.162
Authors: Elisabet Nerpin; Erik Ingelsson; Ulf Risérus; Johan Sundström; Anders Larsson; Elisabeth Jobs; Magnus Jobs; Stein Hallan; Björn Zethelius; Lars Berglund; Samar Basu; Johan Arnlöv Journal: Nephrol Dial Transplant Date: 2011-02-18 Impact factor: 5.992
Authors: Bin Zhu; Junrong Zhang; Qingzhu Zheng; Binhua Dong; Meihua Wang; Jin Liu; Yingping Cao Journal: Cancer Manag Res Date: 2021-05-10 Impact factor: 3.989
Authors: Joanna Gertow; Chang Zhi Ng; Rui Miguel Mamede Branca; Olivera Werngren; Lei Du; Sanela Kjellqvist; Peter Hemmingsson; Annette Bruchfeld; Helen MacLaughlin; Per Eriksson; Jonas Axelsson; Rachel M Fisher Journal: Kidney Int Rep Date: 2017-07-29